Mycophenolate Mofetil in Multiple Sclerosis

@article{Frohman2004MycophenolateMI,
  title={Mycophenolate Mofetil in Multiple Sclerosis},
  author={E. Frohman and K. Brannon and M. Racke and K. Hawker},
  journal={Clinical Neuropharmacology},
  year={2004},
  volume={27},
  pages={80-83}
}
Objective:To describe experience with the use of mycophenolate mofetil (MMF) in the treatment of multiple sclerosis (MS). Background:MMF is a potent immunosuppressant that is a selective inhibitor of inosine 5′-monophosphate dehydrogenase type II, the enzyme responsible for the de novo synthesis of the purine nucleotide guanine within activated T and B lymphocytes and macrophages. Methods:A retrospective review of experience in treating 79 MS patients with MMF (61 with secondary progressive, 14… Expand
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients
TLDR
The results suggest that MMF can improve or stabilise MS patients and can be used as an alternative therapy. Expand
Mycophenolate mofetil in the treatment of multiple sclerosis: a preliminary report.
TLDR
The preliminary results support the use of MMF, a cheap and well-tolerated drug, as first line disease modifying drug in MS and long-term results are required for validating the preliminary conclusions. Expand
Mycophenolate mofetil and neurological diseases
TLDR
Experiences with the use of mycophenolate mofetil in neurological diseases showed that MMF is well tolerated and may be useful in some patients, and preliminary results are very promising. Expand
Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients
TLDR
MMF did not affect disease progression but did influence relapse rate, and other medication options should be considered before MMF in advanced progressive patients. Expand
Mycophenolate mofetil and neurological diseases
TLDR
Experiences with the use of mycophenolate mofetil in neurological diseases showed that MMF is well tolerated and may be useful in some patients, and preliminary results are very promising. Expand
Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
  • M. Etemadifar, M. Kazemi, +4 authors A. Maghzi
  • Medicine
  • Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
  • 2011
TLDR
Combination of MMF with IFNB-1a in patients with RRMS is well tolerated, but the efficacy of such combination was not statistically significant in this pilot study and deserves further investigation with a larger sample size and a longer follow-up. Expand
Mycophenolate Mofetil for the Treatment of Multiple Sclerosis-associated Uveitis
TLDR
Mycophenolate mofetil (MMF) had beneficial effects on vision and intraocular inflammation with an acceptable safety profile and systemic adverse effects were transient and minor in severity. Expand
Evidence for efficacy of a drug widely used without authorisation in multiple sclerosis: mycophenolate mofetil
  • J. Kira
  • Medicine
  • Journal of Neurology, Neurosurgery & Psychiatry
  • 2013
TLDR
The efficacy of MMF has been examined in several preliminary prospective studies using relatively small numbers of active relapsing–remitting MS patients, in which MMF was introduced as an add on therapy for interferon β. Expand
Mycophenolate mofetil for relapsing-remitting multiple sclerosis.
TLDR
The evidence from one small study was insufficient to determine the effects of MMF as an add-on therapy for interferon β-1a in new-onset RRMS participants, and two review authors independently selected the trials for inclusion, assessed trial quality, and extracted data. Expand
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
TLDR
Mycophenolate is associated with reduction in relapse frequency and stable or reduced disability in patients with NMO spectrum disorders, and it is concluded that attack prevention with immunosuppressive therapy is the mainstay of preventing disability. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Mycophenolate-mofetil in the treatment of refractory multiple sclerosis
TLDR
The beneficial effects in five patients demonstrate that MMF may be of value in the treatment of MS, and the question of whether more responsive patients would be found in an unselected group requires further study. Expand
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents.
TLDR
Mycophenolate mofetil appears to be a safe and effective alternative immunosuppressant for extra-renal and renal disease in SLE not responding to conventional Immunosuppressive treatment. Expand
Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil
TLDR
Mycophenolate mofetil appears to be an attractive treatment option in skin manifestations of SCLE, and seems to be beneficial for patients with steroid‐refractory lesions that are also resistant to treatment with immunosuppressants or antimalarials. Expand
Mycophenolate Mofetil in the Therapy of Severe Myasthenia gravis
TLDR
Considerable improvement of myasthenic symptoms was seen in all patients within 3–6 months after the initiation of this therapy, and mycophenolate mofetil may be considered as a useful alternative in the treatment of severe myASThenia gravis when standard therapeutic regimens fail. Expand
Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis
TLDR
It is believed that mycophenolate mofetil may be useful in some psoriatic patients unresponsive to or intolerant of other treatments or who are at risk of developing nephrotoxicity at higher doses of cyclosporin. Expand
Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome
TLDR
Considerable improvement of clinical symptoms and electromyographic findings were seen within 6 months after the initiation of mycophenolate mofetil, allowing for tapering and discontinuation of methylprednisolone. Expand
Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases
TLDR
The authors report the use mycophenolate mofetil in the treatment of neuromuscular diseases and found that all patients tolerated MM without major side effects. Expand
Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil
TLDR
A patient with severe refractory myasthenia gravis (MG) who experienced an excellent response to mycophenolate mofetil is presented who was placed on escalating doses of pyridostigmine without benefit. Expand
Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases.
TLDR
Three patients with Takayasu arteritis who were dependent on large doses of steroids and had severe signs of steroid toxicity are observed, and how these patients responded to mycophenolate mofetil is described. Expand
Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil.
TLDR
Mycophenolate mofetil in combination with corticosteroids may be useful in the treatment of acute c-ANCA-positive vasculitis. Expand
...
1
2
3
...